TAVR replacement of Stenotic Aortic Valve with ACURATE Neo2 Valve.

Trial ID:
Paul S. Teirstein, M.D., FACC
The study will compare the safety and effectiveness of the investigational ACURATE Valve, compared to other commercially available TAVR devices (Control Valves).
*Have diagnosed severe symptomatic native aortic stenosis. <br>*Have NYHA Functional Class = II.<br>*Be capable and willing to return to the study hospital for all required scheduled follow up visits.<br>*Be able to take the protocol-required medications<br><br>

Contact Info:

  • CRS Leadership
  • CRSLeadership@scrippshealth.org